血清MCP-1、IMA水平对后循环脑梗死患者血管内介入治疗预后的影响

Influences of serum MCP-1 and IMA levels on the prognosis of intravascular interventional therapy in patients with posterior circulation cerebral infarction

目的分析血清单核细胞趋化蛋白1(MCP-1)、缺血修饰白蛋白(IMA)水平对后循环脑梗死(PCCI)患者血管内介入治疗预后的影响。方法前瞻性选择2018年10月至2020年10月南阳市中心医院收治的108例PCCI患者作为研究对象,男65例,女43例,年龄(48.78±3.51)岁,均接受血管内介入治疗,治疗前检测血清MCP-1、IMA水平。分析血清MCP-1、IMA水平对PCCI患者血管内介入治疗预后的影响;绘制受试者工作特征曲线(ROC),分析血清MCP-1、IMA水平对PCCI患者血管内介入治疗预后的预测价值。结果血管内介入治疗后3个月,108例患者中预后良好55例(50.93%),预后不良53例(49.07%);预后不良组患者血清MCP-1、IMA水平分别为(16.83±2.95)ng·dl^(-1)、(10.95±1.85)μg·L^(-1),高于预后良好组(13.76±2.18)ng·dl^(-1)、(8.62±1.67)μg·L^(-1),差异均有统计学意义(均P<0.05)。logistic回归分析结果显示,血清MCP-1、IMA水平可影响PCCI患者血管内介入治疗预后(均OR>1,P<0.05)。绘制ROC发现,血清MCP-1、IMA水平及联合检测预测PCCI患者血管内介入治疗预后的曲线下面积(AUC)>0.7,具有较高预测价值。结论PCCI患者血管内介入治疗预后受血清MCP-1、IMA水平的影响,且可根据上述指标水平预测患者血管内介入治疗预后。

Objective To analyze the influences of serum monocyte chemoattractant protein-1(MCP-1)and ischemia modified albumin(IMA)levels on the prognosis of intravascular interventional therapy in patients with posterior circulation cerebral infarction(PCCI).Methods A total of 108 patients with PCCI treated in Nanyang Central Hospital from October 2018 to October 2020 were prospectively selected as the research subjects,including 65 males and 43 females,with an age of(48.78±3.51)years old.They all received intravascular interventional therapy,and the levels of serum MCP-1 and IMA were measured before the treatment.The influences of serum MCP-1 and IMA levels on the prognosis of intravascular interventional therapy in patients with PCCI were analyzed;the receiver operating characteristic curve(ROC)was drawn to analyze the predictive values of serum MCP-1 and IMA levels for the prognosis of PCCI patients after intravascular interventional therapy.Results Three months after intravascular interventional therapy,of the 108 patients,55 cases(50.93%)had a good prognosis and 53 cases(49.07%)had a poor prognosis.Serum MCP-1 and IMA levels in the poor prognosis group were(16.83±2.95)ng·dl^(-1) and(10.95±1.85)μg·L^(-1),respectively,which were higher than those in the good prognosis group[(13.76±2.18)ng·dl^(-1) and(8.62±1.67)μg·L^(-1)],with statistically significant differences(both P<0.05).Logistic regression analysis showed that serum MCP-1 and IMA levels could affect the prognosis of PCCI patients after intravascular interventional therapy(both OR>1,P<0.05).ROC mapping showed that the areas under the curve(AUC)of serum MCP-1 and IMA levels and combined detection for predicting the prognosis of intravascular interventional therapy in PCCI patients were>0.7,with high predictive values.Conclusion The prognosis of intravascular interventional therapy in patients with PCCI is affected by the levels of serum MCP-1 and IMA,and the prognosis of intravascular interventional therapy can be predicted according to the above indexes.